Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
Cell
    July 2022
  1. TUEKPRAKHON A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, et al
    Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
    Cell. 2022;185:2422-2433.
    >> Share

  2. KAO J, Frankland PW
    COVID fog demystified.
    Cell. 2022;185:2391-2393.
    >> Share

  3. FERNANDEZ-CASTANEDA A, Lu P, Geraghty AC, Song E, et al
    Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation.
    Cell. 2022;185:2452-2468.
    >> Share

  4. ZHANG Z, Mateus J, Coelho CH, Dan JM, et al
    Humoral and cellular immune memory to four COVID-19 vaccines.
    Cell. 2022;185:2434-2451.
    >> Share

    June 2022
  5. XU K, Gao P, Liu S, Lu S, et al
    Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
    Cell. 2022;185:2265-2278.
    >> Share

  6. NUTALAI R, Zhou D, Tuekprakhon A, Ginn HM, et al
    Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
    Cell. 2022;185:2116-2131.
    >> Share

  7. YAMASOBA D, Kimura I, Nasser H, Morioka Y, et al
    Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
    Cell. 2022;185:2103-2115.
    >> Share

  8. CHATURVEDI S, Pablo M, Wolf M, Rosas-Rivera D, et al
    Disrupting autorepression circuitry generates "open-loop lethality" to yield escape-resistant antiviral agents.
    Cell. 2022;185:2086-2102.
    >> Share

    May 2022
  9. YEUNG ML, Teng JLL, Yuen KY
    Response to Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity.
    Cell. 2022;185:1840-1841.
    >> Share

  10. BATLLE D, Monteil V, Garreta E, Hassler L, et al
    Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity.
    Cell. 2022;185:1837-1839.
    >> Share

  11. GOEL RR, Painter MM, Lundgreen KA, Apostolidis SA, et al
    Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine.
    Cell. 2022;185:1875-1887.
    >> Share

    April 2022
  12. YING B, Scheaffer SM, Whitener B, Liang CY, et al
    Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
    Cell. 2022;185:1572-1587.
    >> Share

  13. GAGNE M, Moliva JI, Foulds KE, Andrew SF, et al
    mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.
    Cell. 2022;185:1556-1571.
    >> Share

  14. SERVELLITA V, Syed AM, Morris MK, Brazer N, et al
    Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
    Cell. 2022;185:1539-1548.
    >> Share

  15. CHANDRASHEKAR A, Yu J, McMahan K, Jacob-Dolan C, et al
    Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
    Cell. 2022;185:1549-1555.
    >> Share

  16. RODDA LB, Morawski PA, Pruner KB, Fahning ML, et al
    Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.
    Cell. 2022;185:1588-1601.
    >> Share


  17. Bringing research to the intensive care setting.
    Cell. 2022;185:1275-1278.
    >> Share


  18. Learning lessons from lipids to make COVID-19 vaccines.
    Cell. 2022;185:1279-1282.
    >> Share

  19. LI C, Zhan W, Yang Z, Tu C, et al
    Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.
    Cell. 2022;185:1389-1401.
    >> Share

  20. YEN M, Ren J, Liu Q, Glassman CR, et al
    Facile discovery of surrogate cytokine agonists.
    Cell. 2022;185:1414-1430.
    >> Share

  21. QU L, Yi Z, Shen Y, Lin L, et al
    Circular RNA vaccines against SARS-CoV-2 and emerging variants.
    Cell. 2022 Apr 1. pii: S0092-8674(22)00394-4. doi: 10.1016/j.cell.2022.
    >> Share

    March 2022
  22. TANGYE SG, Burnett DL, Bull RA
    Getting to the (germinal) center of humoral immune responses to SARS-CoV-2.
    Cell. 2022;185:945-948.
    >> Share

  23. ZAZHYTSKA M, Kodra A, Hoagland DA, Frere J, et al
    Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia.
    Cell. 2022;185:1052-1064.
    >> Share

  24. ROLTGEN K, Nielsen SCA, Silva O, Younes SF, et al
    Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.
    Cell. 2022;185:1025-1040.
    >> Share


  25. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
    Cell. 2022;185:916-938.
    >> Share

  26. SU Y, Yuan D, Chen DG, Ng RH, et al
    Multiple early factors anticipate post-acute COVID-19 sequelae.
    Cell. 2022;185:881-895.
    >> Share

  27. AFKHAMI S, D'Agostino MR, Zhang A, Stacey HD, et al
    Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
    Cell. 2022;185:896-915.
    >> Share

  28. TARKE A, Coelho CH, Zhang Z, Dan JM, et al
    SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
    Cell. 2022;185:847-859.
    >> Share

  29. CUI Z, Liu P, Wang N, Wang L, et al
    Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron.
    Cell. 2022;185:860-871.
    >> Share

    February 2022
  30. BORRIELLO F, Poli V, Shrock E, Spreafico R, et al
    An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.
    Cell. 2022;185:614-629.
    >> Share

  31. MUDD PA, Minervina AA, Pogorelyy MV, Turner JS, et al
    SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.
    Cell. 2022;185:603-613.
    >> Share

  32. WESEMANN DR
    Omicron's message on vaccines: Boosting begets breadth.
    Cell. 2022;185:411-413.
    >> Share

  33. SIDDLE KJ, Krasilnikova LA, Moreno GK, Schaffner SF, et al
    Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak.
    Cell. 2022;185:485-492.
    >> Share

  34. GEORG P, Astaburuaga-Garcia R, Bonaguro L, Brumhard S, et al
    Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
    Cell. 2022;185:493-512.
    >> Share

  35. HOFFMANN M, Kruger N, Schulz S, Cossmann A, et al
    The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
    Cell. 2022;185:447-456.
    >> Share

  36. COLLINS F
    Francis Collins: Reflections on being the NIH Director.
    Cell. 2022;185:401-406.
    >> Share

    December 2021
  37. GRUBAUGH ND, Cobey S
    Of variants and vaccines.
    Cell. 2021;184:6222-6223.
    >> Share

  38. TERMINI CM, Rutaganira FUN, Palavicino-Maggio CB, Spriggs CC, et al
    Using virtual interviewing to create a more accessible hybrid academic job market.
    Cell. 2021;184:6217-6221.
    >> Share

  39. WENDISCH D, Dietrich O, Mari T, von Stillfried S, et al
    SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.
    Cell. 2021;184:6243-6261.
    >> Share

  40. BUSHMAN M, Kahn R, Taylor BP, Lipsitch M, et al
    Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape.
    Cell. 2021;184:6229-6242.
    >> Share

  41. BRIAND SC, Cinelli M, Nguyen T, Lewis R, et al
    Infodemics: A new challenge for public health.
    Cell. 2021;184:6010-6014.
    >> Share

  42. XIAO Y, Lidsky PV, Shirogane Y, Aviner R, et al
    A defective viral genome strategy elicits broad protective immunity against respiratory viruses.
    Cell. 2021;184:6037-6051.
    >> Share

  43. CHATURVEDI S, Vasen G, Pablo M, Chen X, et al
    Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.
    Cell. 2021;184:6022-6036.
    >> Share

    November 2021
  44. KHAN M, Yoo SJ, Clijsters M, Backaert W, et al
    Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb.
    Cell. 2021;184:5932-5949.
    >> Share

  45. KUMAR S, Javed R, Mudd M, Pallikkuth S, et al
    Mammalian hybrid pre-autophagosomal structure HyPAS generates autophagosomes.
    Cell. 2021;184:5950-5969.
    >> Share

  46. PAYNE RP, Longet S, Austin JA, Skelly DT, et al
    Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
    Cell. 2021;184:5699-5714.
    >> Share

    October 2021
  47. CROSS G, Ho JSY, Zacharias W, Jeyasekharan AD, et al
    Emergency drug use in a pandemic: Harsh lessons from COVID-19.
    Cell. 2021;184:5497-5500.
    >> Share


  48. Persistent progress.
    Cell. 2021;184:5293-5296.
    >> Share

  49. SHAPIRO L, Losick R
    Delivering the message: How a novel technology enabled the rapid development of effective vaccines.
    Cell. 2021;184:5271-5274.
    >> Share

    September 2021
  50. MARTIN DP, Weaver S, Tegally H, San JE, et al
    The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages.
    Cell. 2021;184:5189-5200.
    >> Share

  51. CEVIK M, Grubaugh ND, Iwasaki A, Openshaw P, et al
    COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
    Cell. 2021;184:5077-5081.
    >> Share

  52. JACKSON B, Boni MF, Bull MJ, Colleran A, et al
    Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic.
    Cell. 2021;184:5179-5188.
    >> Share


  53. Building and supporting identity in peer review.
    Cell. 2021;184:5071-5072.
    >> Share

  54. ZELLER M, Gangavarapu K, Anderson C, Smither AR, et al
    Emergence of an early SARS-CoV-2 epidemic in the United States.
    Cell. 2021;184:4939-4952.
    >> Share

  55. SPOSITO B, Broggi A, Pandolfi L, Crotta S, et al
    The interferon landscape along the respiratory tract impacts the severity of COVID-19.
    Cell. 2021;184:4953-4968.
    >> Share

  56. HOLMES EC, Goldstein SA, Rasmussen AL, Robertson DL, et al
    The origins of SARS-CoV-2: A critical review.
    Cell. 2021;184:4848-4856.
    >> Share

  57. ZIEGLER CGK, Miao VN, Owings AH, Navia AW, et al
    Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19.
    Cell. 2021;184:4713-4733.
    >> Share

    August 2021
  58. KARLSSON EA, Duong V
    The continuing search for the origins of SARS-CoV-2.
    Cell. 2021;184:4373-4374.
    >> Share

  59. KANG L, He G, Sharp AK, Wang X, et al
    A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation.
    Cell. 2021;184:4392-4400.
    >> Share

  60. NATHAN A, Rossin EJ, Kaseke C, Park RJ, et al
    Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.
    Cell. 2021;184:4401-4413.
    >> Share

  61. ZHOU H, Ji J, Chen X, Bi Y, et al
    Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses.
    Cell. 2021;184:4380-4391.
    >> Share

  62. LIU C, Ginn HM, Dejnirattisai W, Supasa P, et al
    Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
    Cell. 2021;184:4220-4236.
    >> Share

  63. LI D, Edwards RJ, Manne K, Martinez DR, et al
    In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
    Cell. 2021;184:4203-4219.
    >> Share

    July 2021
  64. RESCIGNO M
    Unraveling the long-term effect of influenza vaccines.
    Cell. 2021;184:3845-3847.
    >> Share

  65. WEINGARTEN-GABBAY S, Klaeger S, Sarkizova S, Pearlman LR, et al
    Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.
    Cell. 2021;184:3962-3980.
    >> Share

  66. COPIN R, Baum A, Wloga E, Pascal KE, et al
    The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
    Cell. 2021;184:3949-3961.
    >> Share

    June 2021
  67. YAN L, Yang Y, Li M, Zhang Y, et al
    Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading.
    Cell. 2021;184:3474-3485.
    >> Share

  68. LIU K, Pan X, Li L, Yu F, et al
    Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species.
    Cell. 2021;184:3438-3451.
    >> Share

  69. LIU Y, Soh WT, Kishikawa JI, Hirose M, et al
    An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
    Cell. 2021;184:3452-3466.
    >> Share

  70. HE X, Chandrashekar A, Zahn R, Wegmann F, et al
    Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
    Cell. 2021;184:3467-3473.
    >> Share

  71. HAO Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, et al
    Integrated analysis of multimodal single-cell data.
    Cell. 2021;184:3573-3587.
    >> Share

  72. DENG X, Garcia-Knight MA, Khalid MM, Servellita V, et al
    Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
    Cell. 2021;184:3426-3437.
    >> Share

  73. WIMMERS F, Donato M, Kuo A, Ashuach T, et al
    The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination.
    Cell. 2021 Jun 22. pii: S0092-8674(21)00692-9. doi: 10.1016/j.cell.2021.
    >> Share

  74. CORTI D, Purcell LA, Snell G, Veesler D, et al
    Tackling COVID-19 with neutralizing monoclonal antibodies.
    Cell. 2021;184:3086-3108.
    >> Share

  75. SCHEID JF, Barnes CO, Eraslan B, Hudak A, et al
    B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.
    Cell. 2021;184:3205-3221.
    >> Share

  76. ASARNOW D, Wang B, Lee WH, Hu Y, et al
    Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
    Cell. 2021;184:3192-3204.
    >> Share

    May 2021
  77. BAUMER Y, Powell-Wiley TM
    Interdisciplinary approaches are fundamental to decode the biology of adversity.
    Cell. 2021;184:2797-2801.
    >> Share

  78. GARRETT ME, Galloway J, Chu HY, Itell HL, et al
    High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.
    Cell. 2021;184:2927-2938.
    >> Share

  79. DEJNIRATTISAI W, Zhou D, Supasa P, Liu C, et al
    Antibody evasion by the P.1 strain of SARS-CoV-2.
    Cell. 2021;184:2939-2954.
    >> Share

  80. WILLIAMS WB, Meyerhoff RR, Edwards RJ, Li H, et al
    Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.
    Cell. 2021 May 18. pii: S0092-8674(21)00577-8. doi: 10.1016/j.cell.2021.
    >> Share

  81. ALPERT T, Brito AF, Lasek-Nesselquist E, Rothman J, et al
    Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States.
    Cell. 2021;184:2595-2604.
    >> Share

  82. WASHINGTON NL, Gangavarapu K, Zeller M, Bolze A, et al
    Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
    Cell. 2021;184:2587-2594.
    >> Share

  83. HO JSY, Mok BW, Campisi L, Jordan T, et al
    TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
    Cell. 2021;184:2618-2632.
    >> Share

  84. CLARK SA, Clark LE, Pan J, Coscia A, et al
    SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.
    Cell. 2021;184:2605-2617.
    >> Share

  85. QIU X, Hanage WP, Taylor BP
    Coming to America: Genomic surveillance and how B.1.1.7 arrived in the US.
    Cell. 2021;184:2532-2534.
    >> Share

    April 2021
  86. LEBLANC EV, Colpitts CC
    SARS-CoV-2 RNA: Exclusive friends and common foes.
    Cell. 2021;184:2276-2278.
    >> Share

  87. BOEHM JS
    The power of parent scientists.
    Cell. 2021;184:2263-2270.
    >> Share

  88. HOFFMANN M, Arora P, Gross R, Seidel A, et al
    SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
    Cell. 2021;184:2384-2393.
    >> Share

  89. SURYADEVARA N, Shrihari S, Gilchuk P, VanBlargan LA, et al
    Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
    Cell. 2021;184:2316-2331.
    >> Share

  90. FABIUS JM, Krogan NJ
    Creating collaboration by breaking down scientific barriers.
    Cell. 2021;184:2271-2275.
    >> Share

  91. MCCALLUM M, De Marco A, Lempp FA, Tortorici MA, et al
    N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
    Cell. 2021;184:2332-2347.
    >> Share

  92. GARCIA-BELTRAN WF, Lam EC, St Denis K, Nitido AD, et al
    Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
    Cell. 2021;184:2372-2383.
    >> Share

  93. FLYNN RA, Belk JA, Qi Y, Yasumoto Y, et al
    Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions.
    Cell. 2021;184:2394-2411.
    >> Share

  94. ZHOU D, Dejnirattisai W, Supasa P, Liu C, et al
    Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
    Cell. 2021;184:2348-2361.
    >> Share


  95. The origins of viral infection sleuth.
    Cell. 2021;184:1960-1961.
    >> Share

  96. SCHNEIDER JL, Rowe JH, Garcia-de-Alba C, Kim CF, et al
    The aging lung: Physiology, disease, and immunity.
    Cell. 2021;184:1990-2019.
    >> Share

  97. MILLS RJ, Humphrey SJ, Fortuna PRJ, Lor M, et al
    BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
    Cell. 2021;184:2167-2182.
    >> Share

  98. DEJNIRATTISAI W, Zhou D, Ginn HM, Duyvesteyn HME, et al
    The antigenic anatomy of SARS-CoV-2 receptor binding domain.
    Cell. 2021;184:2183-2200.
    >> Share

  99. SUPASA P, Zhou D, Dejnirattisai W, Liu C, et al
    Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
    Cell. 2021;184:2201-2211.
    >> Share

  100. YEUNG ML, Teng JLL, Jia L, Zhang C, et al
    Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
    Cell. 2021;184:2212-2228.
    >> Share

  101. ZHANG X, Liu Y, Liu J, Bailey AL, et al
    A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.
    Cell. 2021;184:2229-2238.
    >> Share

  102. PEIRIS JSM
    One world, one health.
    Cell. 2021;184:1956-1959.
    >> Share

  103. SCHULTZE JL, Aschenbrenner AC
    COVID-19 and the human innate immune system.
    Cell. 2021;184:1671-1692.
    >> Share

  104. YU B, Qi Y, Li R, Shi Q, et al
    B cell-specific XIST complex enforces X-inactivation and restrains atypical B cells.
    Cell. 2021;184:1790-1803.
    >> Share

  105. LIU C, Martins AJ, Lau WW, Rachmaninoff N, et al
    Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19.
    Cell. 2021;184:1836-1857.
    >> Share

  106. WINKLER ES, Gilchuk P, Yu J, Bailey AL, et al
    Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
    Cell. 2021;184:1804-1820.
    >> Share

  107. ANDREANO E, Nicastri E, Paciello I, Pileri P, et al
    Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
    Cell. 2021;184:1821-1835.
    >> Share

  108. REN X, Wen W, Fan X, Hou W, et al
    COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas.
    Cell. 2021;184:1895-1913.
    >> Share

  109. SUN L, Li P, Ju X, Rao J, et al
    In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
    Cell. 2021;184:1865-1883.
    >> Share

  110. ANDERSON EM, Goodwin EC, Verma A, Arevalo CP, et al
    Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
    Cell. 2021;184:1858-1864.
    >> Share

    March 2021
  111. GEBRE MS, Brito LA, Tostanoski LH, Edwards DK, et al
    Novel approaches for vaccine development.
    Cell. 2021;184:1589-1603.
    >> Share

  112. SANDRONE S, Scott G, Anderson WJ, Musunuru K, et al
    Active learning-based STEM education for in-person and online learning.
    Cell. 2021;184:1409-1414.
    >> Share


  113. Scientific misinformation: A perfect storm, missteps, and moving forward.
    Cell. 2021;184:1402-1406.
    >> Share

  114. TOPOL EJ
    Messenger RNA vaccines against SARS-CoV-2.
    Cell. 2021;184:1401.
    >> Share

  115. PILLON NJ, Loos RJF, Marshall SM, Zierath JR, et al
    Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care.
    Cell. 2021;184:1530-1544.
    >> Share

  116. MANN ME, Hall LJ, Dulvy NK
    Scientific impact in a changing world.
    Cell. 2021;184:1407-1408.
    >> Share

  117. THOMSON EC, Rosen LE, Shepherd JG, Spreafico R, et al
    Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.
    Cell. 2021;184:1171-1187.
    >> Share

  118. GRUBAUGH ND, Hodcroft EB, Fauver JR, Phelan AL, et al
    Public health actions to control new SARS-CoV-2 variants.
    Cell. 2021;184:1127-1132.
    >> Share

  119. BROUWER PJM, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, et al
    Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.
    Cell. 2021;184:1188-1200.
    >> Share

  120. SOKAL A, Chappert P, Barba-Spaeth G, Roeser A, et al
    Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
    Cell. 2021;184:1201-1213.
    >> Share

    February 2021
  121. LI Q, Nie J, Wu J, Zhang L, et al
    SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
    Cell. 2021 Feb 23. pii: S0092-8674(21)00231-2. doi: 10.1016/j.cell.2021.
    >> Share

  122. SETTE A, Crotty S
    Adaptive immunity to SARS-CoV-2 and COVID-19.
    Cell. 2021;184:861-880.
    >> Share

  123. NIE X, Qian L, Sun R, Huang B, et al
    Multi-organ proteomic landscape of COVID-19 autopsies.
    Cell. 2021;184:775-791.
    >> Share

  124. ATYEO C, Pullen KM, Bordt EA, Fischinger S, et al
    Compromised SARS-CoV-2-specific placental antibody transfer.
    Cell. 2021;184:628-642.
    >> Share

    January 2021
  125. GARCIA-BELTRAN WF, Lam EC, Astudillo MG, Yang D, et al
    COVID-19-neutralizing antibodies predict disease severity and survival.
    Cell. 2021;184:476-488.
    >> Share

  126. HOANG TN, Pino M, Boddapati AK, Viox EG, et al
    Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
    Cell. 2021;184:460-475.
    >> Share


  127. What happens next.
    Cell. 2021;184:291-292.
    >> Share

  128. HOFFMANN HH, Schneider WM, Rozen-Gagnon K, Miles LA, et al
    TMEM41B Is a Pan-flavivirus Host Factor.
    Cell. 2021;184:133-148.
    >> Share

  129. WANG R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, et al
    Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.
    Cell. 2021;184:106-119.
    >> Share

  130. RODDA LB, Netland J, Shehata L, Pruner KB, et al
    Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
    Cell. 2021;184:169-183.
    >> Share

  131. KARKI R, Sharma BR, Tuladhar S, Williams EP, et al
    Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.
    Cell. 2021;184:149-168.
    >> Share

  132. VOLZ E, Hill V, McCrone JT, Price A, et al
    Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
    Cell. 2021;184:64-75.
    >> Share

  133. DANILOSKI Z, Jordan TX, Wessels HH, Hoagland DA, et al
    Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells.
    Cell. 2021;184:92-105.
    >> Share

  134. WEI J, Alfajaro MM, DeWeirdt PC, Hanna RE, et al
    Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.
    Cell. 2021;184:76-91.
    >> Share

    December 2020
  135. AVANZATO VA, Matson MJ, Seifert SN, Pryce R, et al
    Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.
    Cell. 2020;183:1901-1912.
    >> Share

  136. ZOHAR T, Loos C, Fischinger S, Atyeo C, et al
    Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.
    Cell. 2020;183:1508-1519.
    >> Share

  137. SU Y, Chen D, Yuan D, Lausted C, et al
    Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.
    Cell. 2020;183:1479-1495.
    >> Share

  138. CHEN Y, Zuiani A, Fischinger S, Mullur J, et al
    Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.
    Cell. 2020;183:1496-1507.
    >> Share

  139. GHOSH S, Dellibovi-Ragheb TA, Kerviel A, Pak E, et al
    beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway.
    Cell. 2020;183:1520-1535.
    >> Share

    November 2020
  140. WALLS AC, Fiala B, Schafer A, Wrenn S, et al
    Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Cell. 2020;183:1367-1382.
    >> Share

  141. MECKIFF BJ, Ramirez-Suastegui C, Fajardo V, Chee SJ, et al
    Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19.
    Cell. 2020;183:1340-1353.
    >> Share

  142. BANERJEE AK, Blanco MR, Bruce EA, Honson DD, et al
    SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses.
    Cell. 2020;183:1325-1339.
    >> Share

  143. AID M, Busman-Sahay K, Vidal SJ, Maliga Z, et al
    Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques.
    Cell. 2020;183:1354-1366.
    >> Share

  144. KREYE J, Reincke SM, Kornau HC, Sanchez-Sendin E, et al
    A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Cell. 2020;183:1058-1069.
    >> Share

  145. LEIST SR, Dinnon KH 3rd, Schafer A, Tse LV, et al
    A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.
    Cell. 2020;183:1070-1085.
    >> Share

  146. RYDYZNSKI MODERBACHER C, Ramirez SI, Dan JM, Grifoni A, et al
    Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
    Cell. 2020;183:996-1012.
    >> Share

  147. PICCOLI L, Park YJ, Tortorici MA, Czudnochowski N, et al
    Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Cell. 2020;183:1024-1042.
    >> Share

  148. GRUBER CN, Patel RS, Trachtman R, Lepow L, et al
    Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).
    Cell. 2020;183:982-995.
    >> Share

  149. CLAUSEN TM, Sandoval DR, Spliid CB, Pihl J, et al
    SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
    Cell. 2020;183:1043-1057.
    >> Share

  150. CONSIGLIO CR, Cotugno N, Sardh F, Pou C, et al
    The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
    Cell. 2020;183:968-981.
    >> Share

    October 2020
  151. YURKOVETSKIY L, Wang X, Pascal KE, Tomkins-Tinch C, et al
    Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
    Cell. 2020;183:739-751.
    >> Share

  152. MUKHERJEE S
    Before Virus, After Virus: A Reckoning.
    Cell. 2020;183:308-314.
    >> Share

  153. IWASAKI A, Omer SB
    Why and How Vaccines Work.
    Cell. 2020;183:290-295.
    >> Share

  154. GOLDSTEIN JL
    The Spanish 1918 Flu and the COVID-19 Disease: The Art of Remembering and Foreshadowing Pandemics.
    Cell. 2020;183:285-289.
    >> Share

  155. LI W, Schafer A, Kulkarni SS, Liu X, et al
    High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.
    Cell. 2020;183:429-441.
    >> Share

  156. SEKINE T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, et al
    Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
    Cell. 2020;183:158-168.
    >> Share

  157. AU L, Boos LA, Swerdlow A, Byrne F, et al
    Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study.
    Cell. 2020;183:4-10.
    >> Share

  158. CANETE PF, Vinuesa CG
    COVID-19 Makes B Cells Forget, but T Cells Remember.
    Cell. 2020;183:13-15.
    >> Share

  159. HASSAN AO, Kafai NM, Dmitriev IP, Fox JM, et al
    A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
    Cell. 2020;183:169-184.
    >> Share

  160. IADECOLA C, Anrather J, Kamel H
    Effects of COVID-19 on the Nervous System.
    Cell. 2020;183:16-27.
    >> Share

  161. KANEKO N, Kuo HH, Boucau J, Farmer JR, et al
    Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19.
    Cell. 2020;183:143-157.
    >> Share

    September 2020
  162. SILVIN A, Chapuis N, Dunsmore G, Goubet AG, et al
    Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.
    Cell. 2020;182:1401-1418.
    >> Share

  163. COLUBRI A, Kemball M, Sani K, Boehm C, et al
    Preventing Outbreaks through Interactive, Experiential Real-Life Simulations.
    Cell. 2020;182:1366-1371.
    >> Share

  164. SCHULTE-SCHREPPING J, Reusch N, Paclik D, Bassler K, et al
    Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.
    Cell. 2020;182:1419-1440.
    >> Share

  165. DU S, Cao Y, Zhu Q, Yu P, et al
    Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
    Cell. 2020 Sep 14. pii: S0092-8674(20)31232-0. doi: 10.1016/j.cell.2020.
    >> Share

  166. MORENS DM, Fauci AS
    Emerging Pandemic Diseases: How We Got to COVID-19.
    Cell. 2020;182:1077-1092.
    >> Share

    August 2020
  167. GRUBAUGH ND, Hanage WP, Rasmussen AL
    Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear.
    Cell. 2020;182:794-795.
    >> Share

  168. KORBER B, Fischer WM, Gnanakaran S, Yoon H, et al
    Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
    Cell. 2020;182:812-827.
    >> Share

  169. KREER C, Zehner M, Weber T, Ercanoglu MS, et al
    Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
    Cell. 2020;182:843-854.
    >> Share

  170. BARNES CO, West AP Jr, Huey-Tubman KE, Hoffmann MAG, et al
    Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Cell. 2020;182:828-842.
    >> Share

  171. GEITMANN A
    Travel Less. Make It Worthwhile.
    Cell. 2020;182:790-793.
    >> Share

  172. WANG H, Zhang Y, Huang B, Deng W, et al
    Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
    Cell. 2020;182:713-721.
    >> Share

  173. DAI L, Zheng T, Xu K, Han Y, et al
    A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
    Cell. 2020;182:722-733.
    >> Share

  174. BOUHADDOU M, Memon D, Meyer B, White KM, et al
    The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
    Cell. 2020;182:685-712.
    >> Share

  175. SUN J, Zhuang Z, Zheng J, Li K, et al
    Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.
    Cell. 2020;182:734-743.
    >> Share

  176. HASSAN AO, Case JB, Winkler ES, Thackray LB, et al
    A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.
    Cell. 2020;182:744-753.
    >> Share

    July 2020
  177. EINAV T, Gentles LE, Bloom JD
    SnapShot: Influenza by the Numbers.
    Cell. 2020;182:532-532.
    >> Share

  178. JIANG RD, Liu MQ, Chen Y, Shan C, et al
    Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.
    Cell. 2020;182:50-58.
    >> Share

  179. SHEN B, Yi X, Sun Y, Bi X, et al
    Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.
    Cell. 2020;182:59-72.
    >> Share

  180. CAO Y, Su B, Guo X, Sun W, et al
    Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
    Cell. 2020;182:73-84.
    >> Share

  181. JOYCE MG, Wheatley AK, Modjarrad K
    Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.
    Cell. 2020;182:7-9.
    >> Share

    June 2020
  182. SEMPOWSKI GD, Saunders KO, Acharya P, Wiehe KJ, et al
    Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.
    Cell. 2020;181:1458-1463.
    >> Share

  183. BOST P, Giladi A, Liu Y, Bendjelal Y, et al
    Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.
    Cell. 2020;181:1475-1488.
    >> Share

  184. GRIFONI A, Weiskopf D, Ramirez SI, Mateus J, et al
    Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
    Cell. 2020;181:1489-1501.
    >> Share

  185. ZEGGINI E, Baumann M, Gotz M, Herzig S, et al
    Biomedical Research Goes Viral: Dangers and Opportunities.
    Cell. 2020;181:1189-1193.
    >> Share

  186. ZHANG K, Liu X, Shen J, Li Z, et al
    Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography.
    Cell. 2020;181:1423-1433.
    >> Share

  187. CASANOVA JL, Su HC
    A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.
    Cell. 2020;181:1194-1199.
    >> Share

    May 2020
  188. NETEA MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, et al
    Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.
    Cell. 2020;181:969-977.
    >> Share

  189. BLANCO-MELO D, Nilsson-Payant BE, Liu WC, Uhl S, et al
    Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
    Cell. 2020;181:1036-1045.
    >> Share

  190. ZIEGLER CGK, Allon SJ, Nyquist SK, Mbano IM, et al
    SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.
    Cell. 2020;181:1016-1035.
    >> Share

  191. FAUVER JR, Petrone ME, Hodcroft EB, Shioda K, et al
    Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.
    Cell. 2020;181:990-996.
    >> Share

  192. WRAPP D, De Vlieger D, Corbett KS, Torres GM, et al
    Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
    Cell. 2020;181:1004-1015.
    >> Share

  193. LU J, du Plessis L, Liu Z, Hill V, et al
    Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China.
    Cell. 2020;181:997-1003.
    >> Share

  194. HOU YJ, Okuda K, Edwards CE, Martinez DR, et al
    SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.
    Cell. 2020 May 27. pii: S0092-8674(20)30675-9. doi: 10.1016/j.cell.2020.
    >> Share

  195. OBERFELD B, Achanta A, Carpenter K, Chen P, et al
    SnapShot: COVID-19.
    Cell. 2020;181:954-954.
    >> Share

  196. MONTEIL V, Kwon H, Prado P, Hagelkruys A, et al
    Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
    Cell. 2020;181:905-913.
    >> Share

    April 2020
  197. ABBOTT TR, Dhamdhere G, Liu Y, Lin X, et al
    Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
    Cell. 2020 Apr 29. pii: S0092-8674(20)30483-9. doi: 10.1016/j.cell.2020.
    >> Share

  198. WANDZIK JM, Kouba T, Karuppasamy M, Pflug A, et al
    A Structure-Based Model for the Complete Transcription Cycle of Influenza Polymerase.
    Cell. 2020 Apr 16. pii: S0092-8674(20)30389-5. doi: 10.1016/j.cell.2020.
    >> Share


  199. COVID-19: Navigating Uncertainties Together.
    Cell. 2020;181:209-210.
    >> Share

  200. ZHANG YZ, Holmes EC
    A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.
    Cell. 2020;181:223-227.
    >> Share

  201. HOFFMANN M, Kleine-Weber H, Schroeder S, Kruger N, et al
    SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Cell. 2020;181:271-280.
    >> Share

    March 2020
  202. ZHANG T, Yin C, Boyd DF, Quarato G, et al
    Influenza Virus Z-RNAs Induce ZBP1-Mediated Necroptosis.
    Cell. 2020;180:1115-1129.
    >> Share


  203. The Novel Coronavirus Outbreak: What We Know and What We Don't.
    Cell. 2020;180:1034-1036.
    >> Share

    January 2020
  204. VAHEY MD, Fletcher DA
    Low-Fidelity Assembly of Influenza A Virus Promotes Escape from Host Cells.
    Cell. 2020;180:205.
    >> Share

    May 2019
  205. GARCIA-SASTRE A
    Snatch-and-Grab Inhibitors to Fight the Flu.
    Cell. 2019;177:1367.
    >> Share

    January 2019
  206. MARTIN BE, Brooke CB
    Flu Shows the Power of Diversity.
    Cell. 2019;176.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016